Omeros Corp at Bank of America NAPA Healthcare Conference (Virtual) Transcript

Jun 15, 2021 / 08:30PM GMT
Gregory Allen Harrison - BofA Securities, Research Division - Analyst

Hi, everyone. Welcome to day 2 of the Virtual Napa Conference here at Bank of America. I'm Greg Harrison, one of the analysts on the biotech team. And on behalf of myself and Geoff Meacham, we'd like to welcome Greg Demopulos, CEO of Omeros. We'll jump into Q&A in a moment, but Greg, if you want to make any opening comments, please do so now.

Gregory A. Demopulos - Omeros Corporation - Co-Founder, Chairman, CEO & President

Yes. Thanks, Greg, to you and Geoff and the rest of the team at BofA. We're appreciative of the opportunity to join you folks today. So thanks.

Questions and Answers:

Gregory Allen Harrison - BofA Securities, Research Division - Analyst

Great. So your lead program is a complement inhibitor targeting MASP-2 in lectin pathway. Maybe you can just give an overview of the advantages that you see from your end, looking upstream within complement as opposed to other assets that target later in the cascade like C2 or --
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot